Carregant...
Benefits versus risks of latest therapies in multiple sclerosis: a perspective review
Disease-modifying treatments for multiple sclerosis (MS) have now been available for almost 20 years. Interferon β (IFN-β) products and glatiramer acetate (GA) were the first available options and are now considered first-line agents for the treatment of MS. These medications have several years of f...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4110840/ https://ncbi.nlm.nih.gov/pubmed/25083243 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042098612462599 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|